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Introduction and historical background
The cytokines TNF-α and LTα/β and their receptors play
key roles in the development of the immune system and in
immune regulation, inflammation, and autoimmunity.
Manipulation of these cytokines in their receptors has
revealed numerous aspects of their function in both health
and disease, particularly in autoimmune diseases. Recent
basic studies and corresponding clinical trials have
revealed a major role for TNF-α in the pathogenesis of
rheumatoid arthritis (RA), with a dramatic response in two-
thirds of the patients to TNF blockade, either with a mono-
clonal antibody or with a soluble TNF receptor. Similarly,
recent findings have shown that blockade of LTα/β by
soluble LTβ receptor can suppress the normal immune
response and interfere with the development of auto-
immune diabetes in the NOD mouse.
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Chapter summary
Tumor necrosis factor (TNF)-α and lymphotoxin (LT) α/β play multiple roles in the development and
function of the immune system. This article focuses on three important aspects of the effects of these
cytokines on the immune response and on autoimmunity. In several experimental systems (Jurkat T cells,
murine T-cell hybridomas), TNF-α appears to cause a downregulation of signaling through the TCR,
revealed by changes in calcium flux, activation of p21, p23 and ZAP70, and a decrease in nuclear
activation of NF-κB. Previous and present results suggest that TNF-α interferes in some manner with
signaling through the TCR, at a locus yet to be delineated. Transgenic expression of LTβR-Fc in
nonobese diabetic (NOD) transgenic mice results in prevention of type 1 diabetes in NOD mice as long
as the level of expression of the fusion protein (under the control of the cytomegalovirus promoter)
remains above a level of 2–3 µg/ml. Once the expression levels of the fusion protein have dropped
below this critical level, the diabetic process resumes and the animals become diabetic at 40–50 weeks
of age, whereas nontransgenic littermates develop diabetes by 25–30 weeks of age. The paradoxical
effects of neonatal TNF-α administration in NOD mice in increasing incidence of and hastening onset of
type 1 diabetes, while neonatal anti-TNF administration completely prevents all signs of islet cell
autoimmunity, are due partly to the low levels of CD4+CD25+ T cells in NOD mice. These low levels are
reduced by a further 50% on neonatal administration of nontoxic levels of TNF-α. In contrast, neonatal
administration of anti-TNF-α results in a dramatic increase in the levels of CD4+CD25+ regulatory
T cells, to levels beyond those seen in wild-type untreated NOD mice. TNF-α and LTα/β thus have
pleomorphic regulatory effects on the development and expression of autoimmunity.
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This review will focus primarily on the effects of TNF and
TNF blockade, and of LTα/β and a blockade of this
cytokine with soluble LTβ receptor in several autoimmune
diseases, both in spontaneous models in the mouse and in
patients with autoimmune disease.
Effects of TNF-α α and TNF-α α blockade on
T-cell function in autoimmunity
There is a growing body of evidence that blockade of TNF
action in patients and experimental animals increases
disease activity and severity in some, but not all, T-cell-
dependent autoimmune diseases. Diseases in which block-
ade of TNF action causes exacerbation or prolongation of
pre-existing autoimmune diseases, or the appearance of
new signs of autoimmunity, are presented in Table 1.
Diseases such as multiple sclerosis, experimental allergic
encephalomyelitis, and type 1 diabetes (T1DM) are all T-
cell mediated as well as T-cell dependent. Murine ‘lupus’
in the (NZB × NZW)F1 strain is antibody mediated, but
clearly T-cell dependent for the development of the patho-
genic IgG autoantibodies. The findings presented in
Table 1 have been confirmed in all cases by at least two
separate studies, and in most cases by several studies.
Many possible mechanisms for these results have been
excluded in one or more of the diseases listed. These
excluded mechanisms include alterations in CD4+/CD8+
ratios, alterations in Th1/Th2 ratios, alterations in levels of
expression of Fas and Fas ligand, and effects on levels of
expression of IL-12, IL-4, etc. [8,9].
Several lines of evidence suggest that TNF levels inversely
affect T-cell responsiveness and TCR signal transduction
[4,8–14]. These studies have documented a decrease in
T-cell proliferation, cytokine production, and calcium flux in
normal T cells and TCR transgenic T cells, following
chronic exposure to TNF in both in vitro and  in vivo
studies. More recently, Cope and coworkers [15] have
demonstrated a decrease in phosphorylation of CD3zeta
p21, p23, and ZAP 70 in T-cell hybridomas cultured in
vitro in the presence of nontoxic levels of TNF-α.
In our own laboratory (Munson et al., manuscript in prepa-
ration), in collaboration with the laboratory of Dr Arthur
Weiss, we have found that chronic 5-day exposure of
Jurkat T cells to nontoxic levels of TNF results in a 90%
reduction in TCR-mediated nuclear activation of NF-κB
(as detected by a reporter construct encoding a NF-κB
binding site coupled to the luciferase gene) after TCR
stimulation. These results suggest that the immunostimula-
tory effects of TNF blockade in many autoimmune dis-
eases (Table 1) may be due to release of T cells from
endogenous TNF-α-mediated inhibition. If so, this would
imply that chronic TNF-α exposure in some manner down-
regulates signal transduction mediated by the TCR.
Because TNF has such pleotropic effects, and because
tumor necrosis factor receptor 1 (55 kb) (TNFR1) and
tumor necrosis factor receptor 2 (75 kb) (TNFR2) are so
widely expressed, it is possible, and indeed probable, that
other not mutually exclusive mechanisms may also con-
tribute to the effects presented in Table 1.
Table 1
Diseases in which tumor necrosis factor (TNF) blockade causes exacerbation
Disease Intervention Result Mechanism References
1. Multiple sclerosis Anti-TNF, soluble TNFR Increase in CNS lesions and  ? T-cell activation [1,2]
disease activity
2. Experimental allergic  TNF-α null mutation Failure of usual regression of  ? T-cell activation [3]
encephalomyelitis (EAE) T-cell reactivity; prolonged 
exacerbation of EAE
3a. Murine ‘lupus’ in  TNF administration (adult) 3–4 month delay in disease  ? Inhibition of T-cell activation [4]
(NZB×NZW)F1 mice onset
3b. Murine ‘lupus’ in  Anti-TNF administration (adult) Earlier disease onset with  ? T-cell activation [5]
(NZB×NZW)F1 mice increased severity
3c. Murine ‘lupus’ in  Heterozygous TNF null mutant Earlier disease onset with  ? T-cell activation [6]
(NZB×NZW)F1 mice increased severity
3d. Murine ‘lupus’ in  Anti-IL-10 administration (adult) Delayed onset and decreased  Increase in endogenous TNF,  [5]
(NZB×NZW)F1 mice severity leading to decreased T-cell 
activation
4a. Type 1 diabetes mellitus  TNF i.p. in adult mice Delayed onset, decreased  ? Inhibition of T-cell activation [7]
in (NOD) mice incidence of diabetes
4b. Type 1 diabetes mellitus  Anti-TNF in adult mice Variable, earlier onset with  ? T-cell activation [8]
in (NOD) mice increased incidence
CNS, central nervous system; i.p., intraperitoneally; NOD, nonobese diabetic; TNFR, TNF receptor.S143
Diseases in which TNF blockade is therapeutic
Diseases in which blockade of TNF action has been
shown to be therapeutic are presented in Table 2. Three
diseases (RA, Crohn’s disease, and psoriasis) form an
interesting group that contrasts sharply with the diseases
in which TNF blockade causes exacerbation (Table 1). RA
is thought by many to be a T-cell-mediated disease but,
unlike the diseases in which TNF blockade causes exacer-
bation (Table 1), anti-TNF therapy results in a dramatic
decrease in symptoms, and in some cases a near com-
plete remission, although the disease recurs relatively
promptly after cessation of anti-TNF therapy.
Much less is known or conjectured about the pathogenesis
of Crohn’s disease and psoriasis. With respect to Crohn’s
disease, recent evidence indicates that one of the principal
predisposing genetic factors is a series of mutations in the
NOD 2 gene, a regulator of NF-κB, a master regulator of
genes involved in inflammation [20,21]. These genes are
expressed in monocytes and macrophages, and are thought
to be a part of the innate immune response. The prominence
of macrophage-produced cytokines (IL-1, TNF-α, and IL-6) in
RA and the prominence of a gene expressed in monocytes
and active in the innate immune system suggest that those
diseases in which TNF blockade is therapeutic may primarily
be the result of overproduction of TNF and related cytokines
by macrophages and monocytes. This is perhaps initially trig-
gered by activated T cells, but the major mediator of inflam-
mation is the macrophage rather than the T cell.
Some of the side effects of anti-TNF therapy in RA (devel-
opment of anti-dsDNA antibodies, development of overt
systemic lupus erythematosus, and central nervous system
lesions suggestive of multiple sclerosis [Table 2]) are
known manifestations of the diseases presented in Table 1,
in which blockade of TNF action leads to exacerbation.
Effects of neonatal administration of TNF and anti-TNF
on T1DM in the NOD mouse
Table 3 presents the effects of neonatal administration of
nontoxic doses of TNF-α to newborn NOD mice, which
results in a striking increase in incidence and a much
earlier onset of diabetes. Additionally, administration of
anti-TNF in doses beginning at 20 µg/g body weight and
rising to 100 µg every other day for the first 21 days after
birth results in complete and prolonged (1 year) absence
of both diabetes and almost all signs of islet cell auto-
immunity [10]. Recent evidence has shown that NOD mice
treated in the neonatal period with TNF have a further
sharp decrease in their already low levels of CD4+CD25+
regulatory T cells. Conversely, anti-TNF treatment in the
neonatal period results in a dramatic increase in these
CD4+CD25+ regulatory T cells. Preliminary studies
suggest that the increase in CD4+CD25+ T cells alone is
sufficient to explain the complete prevention of T1DM,
since regular transfer of small numbers of these T cells to
young NOD mice prevents the development of T1DM.
While this effect on regulatory T cells may be the primary
explanation for the effect of neonatal TNF and anti-TNF on
T1DM, there is another possibility. It has been postulated
[9] that, by decreasing TCR signaling, neonatal TNF expo-
sure results in a decrease in thymic T-cell-negative selec-
tion, particularly of autoreactive T cells. Correspondingly,
neonatal exposure to anti-TNF, by increasing signaling
through the TCR, may result in an increase in thymic
T-cell-negative selection of autoreactive T cells, thus pre-
venting diabetes.
The second model of T1DM presented in Table 3 is that
induced in C57BL/6 mice by introduction of a transgene
encoding  the rat insulin promoter coupled to the TNF-α
coding sequence. These mice develop early severe insulitis,
Available online http://arthritis-research.com/content/4/S3/S141
Table 2
Diseases in which tumor necrosis factor (TNF) blockade is therapeutic
Disease Intervention Result Mechanism Reference
1a. Rheumatoid arthritis Anti-TNF, soluble TNFR 65% of patients have a dramatic  Blockade of TNF-induced  [16]
decrease in disease activity inflammatory response 
(? decreased macrophage activation)
1b. Rheumatoid arthritis Anti-TNF, soluble TNFR Up to 15% of patients develop  ? T-cell activation [16]
α-dsDNA antibodies. 0.2% develop 
mild SLE
1c. Rheumatoid arthritis Anti-TNF, soluble TNFR A few patients develop CNS  ? T-cell activation [17]
findings suggestive of MS
2. Crohn’s disease Anti-TNF, soluble TNFR Dramatic decrease in disease activity  ? Decreased monocyte/macrophage  [18]
in up to 80% of patients activation
3. Psoriasis Anti-TNF Dramatic clearing of skin lesions,  Blockade of TNF-induced  [19]
decrease in associated arthritis inflammation
CNS, central nervous system; MS, multiple sclerosis; SLE, systemic lupus erythematosus; TNFR, TNF receptor.S144
due to the overexpression of TNF in the β-islet cells.
Despite this severe continuing insulitis, however, these
transgenic animals never develop diabetes, and can be
induced to do so only on introduction of a second trans-
gene, rat insulin promoter-B7.1 [11,12].
Analysis of this model indicates that there is an increase in
the number of macrophages and dendritic cells attracted
to the islets by the local expression of TNF-α. Despite this,
the T cells in the islets of these mice appear to be ‘toler-
ant’ to islet cell autoantigens, and the T cells have under-
gone a Th2 shift in the β-islet cell reactive T-cell
population. While this model appears to be distinct from
that in the wild-type NOD mouse, it is noteworthy that the
severe prolonged insulitis in these animals does not result
in the development of islet cell destruction, but does result
in a form of T-cell tolerance; presumably due to some type
of downregulation or alteration in T-cell function, an effect
similar to the effects described in Table 1 (part 3a).
Potential mechanisms
Among the potential mechanisms by which blockade of
TNF action might increase or activate autoimmunity
(Table 1), an inverse effect of TNF levels on signal trans-
duction through the TCR and/or a direct effect of TNF
levels on T-cell apoptosis in the periphery mediated by
TNFR2 are the most prominent (Table 4).
There are several reasons for the first of these two promi-
nent potential mechanisms. First, it is difficult to envision
how TNF blockade could activate macrophage function,
antigen presentation or any other of the inflammatory func-
tions of TNF-α. Second, several lines of evidence (see
earlier) indicate that in vitro or in vivo exposure to TNF is
capable of decreasing the T-cell response as measured by
T-cell proliferation, cytokine production, and calcium flux.
Third, preliminary studies by Cope and coworkers [15]
and Munson et al. (manuscript in preparation) have shown
that chronic exposure to TNF is capable of decreasing the
activation of several of the proximal proteins in the TCR
signaling pathway, and is also capable of decreasing
TCR-mediated activation of NF-κB. The latter effect is
important, since signaling by TNF through one arm of the
TNF receptor signaling pathway and signaling by the TCR
can both result in activation of NF-κB.
The possibility that TNF acts by increasing T-cell pro-
grammed death via TNFR2 must also be considered, since
both mechanisms could be operative. The functions of
TNFR1 are well characterized and include the induction of
programmed cell death via the caspase-8 pathway, as well
as the activation of a large array of molecules involved in the
inflammatory response, primarily through the activation of
NF-κB. The functions of TNFR2 are less well characterized.
Studies in R1, R2 or double-receptor-deficient mice have
shown that TNFR1 is responsible for a number of host
defense and inflammatory responses [22]. TNFR2-defi-
cient mice have dramatically increased serum levels of
TNF in response to endotoxin, and they show exacerbated
inflammation in several inflammatory models [22]. This
suggests that a primary role of TNFR2 is to suppress or
regulate TNF-mediated inflammatory responses. The
TNFR1 receptor is the high-affinity receptor for soluble
TNF [23], but it is expressed at much lower levels on T
cells and peritoneal exudate macrophages [22]. This
difference in expression levels makes evaluation of the
phenotype of receptor-deficient mice complex. Thus, in
TNFR2-deficient mice, experimental allergic encephalo-
myelitis is a much more severe and acute disease [24]. It
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Table 3
Effect of neonatal tumor necrosis factor (TNF) and anti-TNF therapy on type 1 diabetes (T1DM) models
Model Intervention Result Mechanism References
1a. T1DM in NOD mice TNF, 1–2 µg i.p., q.o.d for  Increased incidence and earlier  ? Further decrease in  [9,10]
21 days from birth onset of diabetes CD4+CD25+ regulatory (A Wu and 
T cells HO McDevitt,
? Decrease in thymic  unpublished 
T-cell-negative selection observations)
1b. T1DM in NOD mice Anti-TNF, 20–100 µg i.p.,  Complete, prolonged (1 year)  Dramatic increase in  [9,10] 
q.o.d. for 21 days from birth absence of diabetes and islet  CD4+CD25+ regulatory  (A Wu and 
cell autoimmunity T cells HO McDevitt, 
unpublished 
? Increase in thymic  observations)
T-cell-negative selection
2. T1DM in C57BL/6  TNF overexpressed in β cells Severe insulitis, but diabetes  RIP-TNF appears to have  [11,12]
mice expressing RIP-TNF never occurs (unless transgenic  induced a Th2 shift in 
RIP-B7.1 is introduced) islet-reactive T cells
i.p., intraperitoneally; NOD, nonobese diabetic; q.o.d., every other day; RIP, rat insulin promoter; Th2, T helper cell type 2.S145
is not clear whether this is due to the lack of a downregu-
latory influence of TNFR2 or to the increased levels of TNF
that are released in inflammatory responses because of
the lack of the R2 receptor [25–31].
The TNF and TCR signaling pathways
With respect to the specific effects of TNF on signal trans-
duction through the TCR, it should be noted that Cope
and coworkers have reported that chronic TNF exposure
of T-cell hybridomas results in a downregulation of activa-
tion of CD3zeta p21 and 23 and ZAP 70 [15]. It is not
clear how TNF exposure leads to a decrease in the activa-
tion of these proximal TCR signal transduction proteins.
However that decreased activation is achieved, it would
be expected to lead to a decrease in activation of PLC-γ
and PKC, and a corresponding decrease in the activation
pathway from CD28 to NF-κB.
As noted earlier, Munson et al. (manuscript in preparation)
have shown in Jurkat T cells that chronic exposure to low
levels of TNF-α leads to a striking reduction in TCR-
induced NF-κB activation after a 5-day period of incuba-
tion. TNF exposure may act through both pathways to
result in a decrease in NF-κB activation. This would be
expected to result in a decrease in T-cell activation and
T-cell response. Conversely, exposure to anti-TNF and
blockade of all endogenous TNF should prevent the
normal endogenous TNF effects on NF-κB activation. In
both these latter observations [15] (Munson et al., manu-
script in preparation), the pathways and signaling proteins
that are affected by chronic exposure to TNF are
unknown, and they are extremely difficult to identify
because of the complexity of both signaling pathways.
Actual and potential interactions between cell receptor
signaling pathways (receptor cross-talk): interaction between
TNF-α and the insulin receptor
Insulin resistance is an important metabolic abnormality
often associated with stress, infections, cancer and
obesity, and is especially prominent in non-insulin-depen-
dent diabetes. Increased production of TNF-α is frequently
observed in the first three of these conditions.
In obesity, it has been observed that adipocytes produce
low levels of TNF-α that increase in obesity [32]. In 1994,
Spiegelman and associates found that TNF-α inhibits sig-
naling from the insulin receptor [33] and that this was
associated with reduced tyrosine kinase activity of the
insulin receptor [34]. Subsequently, Spiegelman’s group





1. Adult TNF therapy (delays type 1 diabetes, prevents β-cell  1. A decrease in TCR signal transduction and effector T-cell function 
destruction, and delays glomerulonephritis in B/WF1 mice) mediated through TNFR1
2. An increase in T-cell apoptosis mediated by TNFR2
3. Very little effect has been found on CD4+CD25+ regulatory T cells 
in adult mice
2. Adult anti-TNF therapy (variably hastens type 1 diabetes,  1. An increase in TCR signal transduction and effector T-cell function 
increases B/W F1 nephritis, and increases late EAE) through TNFR1
2. A decrease in T-cell apoptosis through TNFR2
3. Very little effect has been found on CD4+CD25+ regulatory T cell 
numbers by anti-TNF
3. Neonatal TNF therapy (increases diabetes incidence and hastens  1. Further decreases CD4+CD25+ regulatory T cells, possibly via 
onset in NOD mice) TNFR2-mediated T-cell apoptosis
2. Possible activation of macrophages and dendritic cells, increasing 
insulitis
3. A decrease in TCR signal transduction via TNFR1, permitting 
potentially autoreactive T cells to escape negative selection, 
emigrate to the periphery and cause diabetes
4. Neonatal anti-TNF therapy (completely prevents type 1  1. Dramatically increases CD4+CD25+ regulatory T cells, possibly by 
diabetes in NOD mice) blocking TNFR2-mediated T-cell apoptosis
2. Possibly decreases macrophage and dendritic cell activation so 
that regulatory T cells can function effectively
3. Possibly increases TCR signal transduction so that autoreactive 
T cells are negatively selected in the thymus and/or in the periphery
EAE, experimental allergic encephalomyelitis; NOD, nonobese diabetic; TCR, T-cell receptor; TNF, tumor necrosis factor; TNFR1, tumor necrosis
factor receptor 1 (55 kb); TNFR2, tumor necrosis factor receptor 2 (75 kb).S146
receptor was due to the induction of serine phosphorylation
of insulin receptor substrate-1 (IRS-1). Serine phosphoryla-
tion converts IRS-1 into an inhibitor of insulin receptor tyro-
sine kinase activity [35]. (In 1997, Hotamisligil and coworkers
also demonstrated that TNF contributes to obesity by
increasing the release of leptin from adipocytes [36].)
The effects of TNF on signaling through the insulin recep-
tor were verified earlier this year when White and cowork-
ers [37] showed that TNF-α, insulin, and insulin growth
factor-1 all act to serine phosphorylate IRS-1 on serine
307. Serine 307 phosphorylation of IRS-1 by TNF-α
requires the action of MEK (also activated in the TNF sig-
naling pathway), while serine 307 phosphorylation by
insulin and insulin growth factor-1 requires association of
JNK-1 with IRS-1, and the activation of the phosphatidyli-
nositol 3-kinases.
This is an excellent example of receptor cross-talk. Insulin,
insulin growth factor-1 and TNF-α all stimulate inhibitory
phosphorylation of serine 307 on IRS-1 but do so through
the use of different kinase pathways, all intersecting at
IRS-1 and serine 307. A similar type of interaction may
explain many other receptor cross-talk phenomena, possi-
bly including the effect of TNF on downregulation of sig-
naling through the TCR.
Interactions between TNF and IL-10
As noted by Ishida et al. [5], chronic administration of anti-
IL-10 to adult (3–4 months old) (NZB × NZW)F1 female
mice (which would be expected to remove the inhibitory
effects of IL-10 and to lead to an exacerbation of disease)
paradoxically results in a delay in the onset of glomerulo-
nephritis. This paradoxical result is almost entirely due to
the failure of IL-10 to downregulate TNF-α production by
macrophages and T cells, since simultaneous administra-
tion of anti-TNF with anti-IL-10 results in no effect on
disease in this model. Thus, endogenous TNF, unopposed
by IL-10, exerts the same delaying and preventive effect
that is seen with administration of TNF in these mice [4,5].
(Anti-TNF administration alone caused a much earlier
onset of fatal nephritis in these mice [5].)
It is clear from the observations already cited [4,5] that
TNF-α, IFN-γ, and other inflammatory cytokines have an
intimate reciprocal relationship with IL-10 [38]. This is
another example of receptor cross-talk, in this case ‘cross-
inhibition’. When this inhibition is released, macrophages
are then capable of increasing their production of inflam-
matory cytokines such as TNF.
Interactions between TNF and the TCR
Developing evidence [9,15] (Munson et al., manuscript in
preparation) has shown that chronic TNF exposure down-
regulates components of both the TNF and the TCR sig-
naling pathways. This evidence indicates that TNF has an
effect both at the level of NF-κB expression, a very distal
part of activation through both the TNF and TCR, and at
the very proximal locus of activation of the CD3 compo-
nents of the TCR.
Effect of TNF-α α on Jurkat TCR activation
Jurkat T cells were cultured in the presence or absence of
human recombinant TNF (10 ng/ml) for 1–6 days. Cells
were then transfected with various transcription factor
binding site–luciferase reporter constructs, incubated
overnight, and washed and stimulated with phorbol 12-
myristate 13-acetate and ionomycin or with anti-CD3
alone or in combination with anti-CD28, in the absence of
TNF. Cells were cotransfected with a plasmid encoding a
truncated CD25 molecule that could be used for normaliz-
ing the transfection efficiency by staining for anti-CD25
and performing FACS analysis.
TNF treatment for 3–5 days resulted in an 86% decrease
in NF-κB-binding to a class I NF-κB binding site–
luciferase reporter construct following stimulation with
phorbol 12-myristate 13-acetate and ionomycin, and
resulted in an 83% decrease following stimulation with
anti-CD3 + anti-CD28 after normalization for transfection
efficiency. Likewise, TNF treatment resulted in similar
decreases in AP-1 binding to an AP-1 luciferase reporter,
as well as decreases in luciferase production from a dual
NF–AT–AP-1 composite reporter. Phosphoblots revealed
very little difference in phosphorylation.
The findings cited in previous sections indicate that expo-
sure to TNF-α affects both proximal and distal parts of the
TCR signal transduction pathways. To obtain a survey of
changes in expression (either up or down) in components
of both the TNF and TCR signaling pathways, experiments
currently underway will utilize gene expression profiling as
the first step in assessing the effect of chronic TNF-α
exposure on TCR signal transduction. These experiments
will utilize the ‘lymphochip’ originally used by Alizadeh et
al. [39] to analyze gene expression in large B-cell lym-
phoma and, more recently, in Jurkat T cells under a variety
of stimulation conditions. These experiments are currently
in progress and should permit a more comprehensive
assessment of changes in gene expression in both of
these receptor signaling pathways. An understanding of
precisely how TNF exposure indirectly regulates TCR
signal transduction may lead to the development of
methods for compensating for the effects of TNF blockade
in those autoimmune diseases where this is an appropri-
ate therapeutic measure.
The role of LTα α/β β and LTβ β receptor in
autoimmunity
Administration of the soluble extracellular domain of LTα/β
coupled to the Fc fragment of IgG as a fusion protein
(LTβR-Fc) to NOD mice, either by injection [40] or by
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transgenic expression transcribed from the cytomegalo-
virus (CMV) promoter [41], prevents T1DM in NOD mice.
The mechanisms of this prevention and the possible unde-
sirable side effects of these interventions are currently
unknown. There are three principal, nonexclusive mecha-
nisms for the effects of LTβ receptor blockade.
The first mechanism is prevention of MAdCAM-1 expres-
sion, causing defective T-cell, B-cell, and dendritic-cell
homing and localization to peripheral lymphoid organs.
Second is the interruption of the positive feedback circuit
between LTαβ/LTβ receptor, B lymphocyte chemoattrac-
tant (BLC) and BLR-1 (and SLC and ELC), resulting in
improper localization of T cells, B cells, and dendritic cells
within the spleen and the lymph nodes, thus causing
altered or defective T cell, B cell, and antigen-presenting
cell (APC) interactions [40,41]. Finally, since soluble LTβ
receptor binds both LTα/β and LIGHT (whose cognate
receptor is the herpes virus entry mediator [HVEM]), the
immunoregulatory effects of the soluble LTβR-Fc may be
mediated by blockade of the interaction between LIGHT,
LTα/β, and the LTβ receptor.
There is abundant evidence (reviewed in [42–44])
describing the critical role of LTα/β and the LTβ receptor
in the development of the immune system. This ligand–
receptor pair, as well several other ligand–receptor pairs
within the TNF-α superfamily, and a number of transcrip-
tion factors, chemokines and chemokine receptors have all
been shown to be required for proper lymph-node genesis
[42–50]. Many of these gene products operate at the very
earliest stages of lymph-node formation, as well as at later
stages in this process. These effects are beyond the
scope of the present discussion, which will focus on the
effects of the lack of the LTβ receptor on immune system
function, primarily in autoimmunity.
Inhibition of LTαβ signaling through the LTβ receptor in
adult mice, by the use of a blocking monoclonal antibody
against LTβ receptor or a soluble LTβR-Fc fusion protein,
induces marked changes in mice receiving this treatment
[40,41,51–54]. In the spleen, discreet B-cell follicles are
markedly reduced or absent, follicular dendritic cell (FDC)
clusters are lacking, and the marginal zone shows radical
changes, with absence of staining with MOMA-1 (a
marker for marginal metallophilic macrophages) and
reduced staining for ER-TR9 on marginal zone
macrophages. In addition, the normal staining for
MAdCAM-1 in the marginal zone is absent in treated mice.
The normal boundary between the B-cell and T-cell zones
in the white pulp of the spleen is disrupted, and the popu-
lation of ER-TR7+ reticular fibroblasts normally seen
around the outside of the white pulp in the marginal zone
is absent. Furthermore, germinal centers did not form in
these mice following immunization with sheep red blood
cells [55].
A single injection of LTβR-Fc was sufficient to eliminate
MAdCAM-1 expression 1 week later [40]. Some of the
other changes noted earlier required several injections of
the fusion protein. Several injections of the LTβR-Fc fusion
protein resulted in a progressive decrease in the level of
sheep red blood cell-specific IgG1, IgG2a, and IgM
responses [40].
Similar changes in splenic architecture, B-cell and T-cell
zone abnormalities, and absence of staining for MAdCAM-
1 were also seen in BALB/c mice expressing a transgenic
LTβR-Fc fusion protein under the control of the CMV pro-
moter [55]. In this transgenic model, the CMV promoter
does not become activated until days 2–3 after birth, by
which time the development and population of lymph
nodes has occurred [55].
The LTβ receptor has two ligands, LTα/β and LIGHT,
another member of the TNF superfamily. The binding of
LIGHT to a second receptor, the HVEM, functions as a
costimulatory ligand–receptor pair that can promote T-cell
proliferation and IFNγ production. Until very recently there
were no reagents that could effectively block LIGHT activity
in vivo. However, a very recent publication [56] has utilized
a soluble HVEM-Fc receptor molecule to block the action
of LIGHT in vivo. These studies showed that the HVEM-
Fc was capable of downregulating the T-cell response to
stimulation with concanavalin A and anti-CD3. Further-
more, multiple injections of HVEM-Fc in 5-week-old to 6-
week-old NOD mice (100 µg per injection) was capable
of decreasing the development of T1DM in the NOD
recipients from 80% at 25 weeks to 25%. It is thus clear
that at least part of the effects of the soluble LTβR-Fc
are due to blockade of the interaction of LIGHT with
HVEM.
The preliminary results presented in this recent study [56]
did not demonstrate the extensive morphological changes
in the spleen and lymph nodes that are seen with the
soluble LTβR-Fc. Clearly, further studies need to be
carried out, but it appears that the effects of LTβR-Fc on
the morphology in the spleen and lymph nodes, the
absence of the marginal zone, and of staining with MOMA-
1 and MadCAM-1 antibodies indicate that the effects of
blockade through the LTβ receptor may involve LTα/β,
LIGHT, and MadCAM-1. The initial results indicate that
LTβR-Fc is more effective in preventing diabetes than is
HVEM-Fc.
Several studies over the past 4 years [13–15] (Munson et
al., manuscript in preparation) have revealed that
LTαβ/LTβ receptor are critical for the development of
natural killer cells, dendritic APCs, and FDCs. Membrane
lymphotoxin is required for dendritic cells to infiltrate the
lymph nodes, while mature FDC networks require LTβ
receptor expression by stromal cells, and LTαβ and TNF
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expression by B cells. FDC development is dependent on
TNF signaling and on LTβ receptor signaling by B cells
(Munson et al., manuscript in preparation).
Mebius et al. [57] showed that, during fetal lymph node
development, the lymph node post-capillary high endothe-
lial venules express MAdCAM-1. This permits the early
lymphoid precursor cells that are α4β7
+, CD45+, CD4+
and CD3– to enter the lymph-node anlage. These cells
also express surface LTβ and the chemokine receptor
BLR-1 (CXCR5), and are capable of becoming natural
killer cells, dendritic APCs, and follicular cells [58–60].
More recently, the mediators by which LTαβ/LTβ receptor
signaling attracts B cells, dendritic APCs, and FDC to the
developing lymph node follicle have been delineated
[61–63]. The picture that emerges from these studies can
be briefly summarized as follows.
Membrane-bound LTβ (produced by CD45+, CD4+, CD3–
lymphoid precursors; see earlier) [57,61–63] binds to LTβ
receptor on stromal cells, leading to the release of BLC
(CCL13). By binding to its receptor on B cells (BLR-1,
CXCR5), BCL attracts B cells to the area in the lymph
nodes and the spleen where production of BLC is
maximal. BLC binding to its receptor leads to B-cell activa-
tion and increased expression of LTαβ, which then leads
to a further increase in expression of BLC, thus establish-
ing a positive feedback loop. By inducing upregulation of
membrane-bound LTαβ, BLC promotes further FDC
development. At the same time, by binding to its receptor,
LTαβ also stimulates induction of SLC (6 C-kine), a weak
B-cell chemoattractant and a strong T-cell chemoattrac-
tant. SLC expression is induced in the region immediately
adjacent to the B-cell region, creating a T-cell-rich region
in the patterns seen in normal lymph nodes and spleen.
LTαβ binding to LTβ receptor also drives the expression of
PNAd, MAdCAM-1 and V-CAM on the post-capillary high
endothelial venules in the developing lymphoid tissue.
SLC expression by endothelial cells and stromal cells,
driven by LTαβ/LTβ receptor, also results in the expres-
sion of ELC by stromal cells. ELC is a strong T-cell
chemoattractant, and the combined action of SLC and
ELC, both binding to CCR7 on T cells, results in the well-
defined segregation of T-cell and B-cell zones in normal
lymphoid tissue. SLC and ELC also bind to CCR7 on den-
dritic cell precursors, thus attracting these cells to the
developing lymphoid architecture.
Chemokines, triggered by the binding of LTαβ to LTβ
receptor (and also by TNF-α binding to its receptors), thus
establish the normal microarchitecture of the lymph node
and the spleen.
From the presented results, it is clear that LTβ receptor
blockade by a LTβR-Fc fusion protein will have multiple
effects. These include a decrease in B-cell production of
LTαβ and BLC, a decrease in expression of PNAd,
MAdCAM-1, and VCAM-1, and a decrease in SLC, and to
a lesser extent, ELC production by stromal cells in the T-
cell zone. These effects explain many of the manifestations
seen in LTβ receptor-deficient and LTβ-deficient mice, and
in mice expressing a LTβR-Fc fusion protein: the loss of
the marginal zone in the spleen; the partial mixing and dis-
ruption of normal T-cell/B-cell zone separation in the
splenic white pulp and lymph nodes; the decrease in
MAdCAM-1 expression; the decrease or absence of
primary follicles and FDC clusters; and the diminution in
T-cell–B-cell–APC interactions, resulting in isotype-
switching defects in specific antibody responses [40,41].
The effect of LTβ βR-Fc on development of T1DM in the
NOD mouse
Injection of relatively large doses of LTβR-Fc in NOD mice
at 12 weeks of age, when insulitis is already well estab-
lished in untreated littermates, results in nearly complete
reversal of insulitis, and in failure to develop diabetes up to
30 weeks of age [40]. Expression of LTβR-Fc, under the
control of the CMV promoter, prevents diabetes in NOD
mice during the period in which expression of the fusion
protein is greater than 2 µg/ml serum [41]. When expres-
sion of the transgene fusion protein drops below this criti-
cal level, however, the mice begin to develop diabetes, at
approximately 40–50 weeks of age, with an incidence of
40% at the end of 1 year.
Both of these findings show that blockade of the
LTαβ/LTβ receptor ligand–receptor system is capable of
downregulating the diabetic process and of preventing the
development of T1DM. Furthermore, the second study
[41] shows that once the level of transgenic fusion protein
has fallen below a critical level, the immune system is per-
fectly capable of reinstituting the diabetic process, leading
to overt clinical diabetes.
It should be noted that in NOD LTβR-Fc mice, there was
very little diminution in insulitis; the size of lymphocytic
infiltrates in the islets and the frequency of insulitis were
indistinguishable between transgene-positive and trans-
gene-negative littermates. This result suggests that the
ability of lymphocytes to migrate to areas of inflammation
is not impaired under this type of treatment, but that the
ability to generate a sufficient diabetogenic T-cell
response that would result in islet cell destruction is
impaired, possibly because of interference with normal T
cell–B cell and T cell–APC interactions.
Two major mechanisms for the effects of LTβR-Fc can
thus be envisioned to explain the observed effects. First, it
is possible that interference with LTαβ binding to its
receptor may decrease the expression of adhesins and
integrins sufficiently to prevent insulitis and diabetes.
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Earlier studies from this laboratory [64] have shown that
administration of a monoclonal antibody to the α4 integrin
in young NOD mice is capable of preventing the develop-
ment of diabetes in these animals. Thus, interference with
α4β7 and α4β1 binding to their respective receptors can
prevent the development of diabetes. However, the finding
that insulitis persists in mice expressing a LTβR-Fc fusion
protein would indicate that these lymphocytes are capable
of entering inflamed areas.
The second possible mechanism for diabetes prevention
may involve the effect of LTαβ/LTβ receptor blockade in
interfering with normal separation between T-cell and B-
cell zones, normal dendritic cell localization, and faulty
interactions of T cells with both B cells and APCs [65]. In
the latter case (i.e. in LTβR-Fc transgenic mice), where the
degree of interference with this ligand–receptor system is
presumably less than that induced by injection of very high
doses of the fusion protein, it may be possible to prevent
the development of diabetes with doses of the fusion
protein that do not seriously interfere with the development
of the normal immune response to environmental antigens.
LTα/β or LTβ null mutations, leading to LTβ deficiency,
prevent autoimmunity not only in NOD mice [40,41], but
also in experimental allergic encephalomyelitis and experi-
mental murine colitis models [66,67]. Near-complete LTαβ
blockade (as in [40]) may cause increased susceptibility
to infection. Conversely, lesser degrees of blockade (as in
[41]) (indicated by the persistence of insulitis) may result
in prevention of diabetogenesis for shorter periods, requir-
ing repeated administration, albeit with less severe
immune suppressive side effects.
Effect of transgenic expression of a soluble LTβ β
receptor on diabetes in NOD mice
F9 LTβR-Fc transgenic mice were followed for the devel-
opment of diabetes by expanding the population to 40–50
female mice, along with nontransgenic littermates. This
experiment was carried out in two different founder lines:
one expressing high (0.8–30 µg/ml) levels of the trans-
gene protein (line 1610), and one expressing lower
(0.38–1.1 µg/ml) levels of the transgene protein (line
201). The 201 line developed diabetes at almost the same
rate as nontransgenic littermates (albeit slightly delayed).
However, female mice in the 1610 line did not develop
diabetes by 30 weeks of age, with the exception of one
animal in a group of 26 females. Examination of these
animals by histology and immunohistochemistry showed
that the 1610 line at 6 and 12 weeks demonstrated similar
anatomical abnormalities in the spleen, the lymph node,
and Peyer’s patches as had been noted in the original
LTβR-Fc transgenic mice described earlier.
In the 1610 NOD line (unlike results in BALB/c mice),
LTβR-Fc protein expression began at relatively high levels
on embryonic day 16.5, reaching 2–30 µg transgene
protein/ml serum by neonatal day 7. Over the next
10–12 weeks, however, the fusion protein concentrations
fell to an average of 3 µg/ml at 10 weeks of age, and to
less than 2 µg/ml at 20 weeks of age [41]. This is an
unusual result, since transcription from the CMV promoter
normally is expected to occur in many tissues throughout
life. In the LTβR-Fc BALB/c mice, levels of LTβR-Fc
remain constant up to 40–50 weeks of age.
Beginning at 35–40 weeks of age, female NOD 1610
mice unexpectedly began to develop diabetes, such that
almost 50% of them developed diabetes by 65 weeks.
Thus, once the LTβR-Fc protein levels fell to 1–2 µg/ml or
lower, the diabetic process was capable of resuming. This
resumption led to the development of T1DM, albeit
15–30 weeks after the nontransgenic littermate females.
Histologic analysis of these mice at 12 and 17–19 weeks
of age showed that they had almost the same degree of
insulitis as seen in control littermates (unlike the results
described by Fu and coworkers [40]). The anatomical
abnormalities in the spleen, which were seen in 4-week-
old to 12-week-old mice, were greatly reduced by
30 weeks of age, with the exception of the redevelopment
of the marginal zone. At 20 and 30 weeks, the structure of
the marginal zone and the expression of MAdCAM-1 and
MOMA-1 were still absent.
Soluble LTβR-Fc fusion protein therefore prevents T1DM in
NOD mice, while levels remain above a critical threshold. Of
great interest, following the decay of fusion-protein expres-
sion, the diabetic process spontaneously restarts and leads
to development of overt diabetes in 50% of mice, with a 30-
week delay (roughly the time period during which higher
levels of the fusion protein were expressed) [41].
The results of this study are significant because they indi-
cate that relatively low levels of a LTβR-Fc fusion protein
are capable of inducing LTβ receptor blockade and of pre-
venting the diabetic process in genetically susceptible
NOD mice. Furthermore, it is clear from this study that no
permanent inhibition of the immune response is induced
by expression of the soluble LTβ receptor. This, of course,
raises the possibility that the LTβR-Fc fusion protein, given
at carefully determined times and doses, might permit pre-
vention of the development of T1DM without significant
degrees of suppression of the immune response to foreign
antigens.
Effect of TNF-α α and its blockade on the
development of CD4+CD25+ regulatory T cells
in the NOD mouse
Introduction
CD4+CD25+ T cells are derived from the thymus and have
gained recent attention as mediators of peripheral tolerance
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[68–70], as well as potentially having a role in the protec-
tion of a transplanted organ from immunological attack
[70]. These cells are found in many mouse strains, includ-
ing the NOD mouse, and in humans. CD4+CD25+ T cells
act essentially as suppressor T cells in the periphery.
These cells are anergic and do not respond to stimulation
with anti-CD3, they are capable of suppressing the
antigen-specific activation of CD4+CD25– T cells, they
require cell–cell contact for this suppression to be effec-
tive, and they may function through the expression of
CTLA-4 molecules on these T cells interacting with B7 (on
either APCs or on the target T-cell population) [68].
The NOD mouse is a well-defined animal model used to
study T1DM. Our laboratory has previously demonstrated
that neonatal administration of TNF (first 3 weeks of life)
accelerates the onset of and increases the incidence of
T1DM in the NOD mouse, while neonatal administration of
anti-TNF completely abrogates all manifestations of T1DM
for up to 1 year [71]. Neonatal TNF administration also
further decreases the number and function of
CD4+CD25+ regulatory T cells. Neonatal administration of
anti-TNF, in contrast, increases the number of
CD4+CD25+ T cells and does not alter the ability of these
cells to suppress disease in a transfer system. These data
suggest that the numbers and function of this regulatory
population may be regulated in either a positive or nega-
tive manner by their cytokine (specifically, TNF) milieu.
Initial results
Ourselves and other workers [72] have shown that the
NOD mouse is numerically deficient in the CD4+CD25+
T-cell population, suggesting a compromised ability to
maintain a state of nonresponsiveness to self-antigens.
Direct supplementation of the neonatal NOD mouse with
three injections of 2 × 105 CD4+CD25+ T cells can signifi-
cantly delay the onset of T1DM in this mouse model. Con-
tinued weekly administration of similar small numbers of
CD4+CD25+ T cells results in failure to develop diabetes
for as long as this treatment is continued. These data high-
light the potential therapeutic value and the potency of
these cells, and are compatible with the concept that the
anti-TNF-induced increase in CD4+CD25+ T cells is the
basis for the failure of anti-TNF-treated mice to develop
diabetes.
Future studies
There is abundant evidence that the thymus of the NOD
mouse displays significant anatomical abnormalities that
are thought to be related to the T1DM disease process.
The precise relationship is unknown. The NOD thymus
exhibits giant perivascular spaces with abnormal retention
of thymocytes and with premature signs of age-associated
breakdown of the thymic epithelium [73–75]. To the
extent that the NOD thymic architecture could influence
the selection and ultimate trafficking of CD4+CD25+
T cells, it becomes important to understand the develop-
ment of CD4+CD25+ T cells in the thymus. There is little
to no information available in this area of study. There is no
data available regarding the development of CD4+CD25+
T cells, and how TNF and/or anti-TNF may affect their
development. These studies are currently under way.
Concluding remarks
The studies presented in this review, as well as a number
of studies from the literature, make it clear that TNF-α and
its receptors (TNFR1 and TNFR2), LTβ receptor and its
LTα/β and LIGHT ligands, and the interaction of LIGHT
with HVEM are all important regulators of the development
and maintenance of structural integrity and function of the
T cells in their interactions with other T cells, B cells and
APCs in the development of the normal immune response
and in the development of autoimmunity. Further under-
standing of the molecular basis for the downregulation of
the immune response produced by pharmacological
doses of TNF-α may lead to the development of new ther-
apies to prevent the excessive stimulation of the immune
system seen in TNF blockade, as occurs in RA.
Furthermore, a detailed understanding of the effects of
soluble LTβ receptor and soluble HVEM receptor on the
function of T cells, and the interaction of T cells with other
T cells and with APCs in the white pulp of the spleen and
the developing follicles in the lymph nodes, may lead to
relatively nontoxic methods for downregulating the autoim-
mune response in diseases such as T1DM, where individ-
uals at risk in the prediabetic stage can be identified and
subjected to this kind of blocking therapy.
Glossary of terms
BLC = B lymphocyte chemoattractant; CMV = cytomegalo-
virus; FDC = follicular dendritic cell; HVEM = herpes virus
entry mediator; IRS-1 = insulin receptor substrate-1;
LTα/β = lymphotoxin α/β (α2β1, aα1β2); LTβR-Fc = the
extra cellular domain of LTα/β coupled to the Fc fragment
of IgG as a fusion protein; NOD = nonobese diabetic;
T1DM = type 1 diabetes, juvenile onset, insulin-dependent
diabetes mellitus, due to insulin deficiency; TNFR1 =
tumor necrosis factor receptor 1 (55 kb); TNFR2 = tumor
necrosis factor receptor 2 (75 kb).
References
1. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW,
von Blomberg BM, Woody JN, Hartung HP, Polman CH: Increased
MRI activity and immune activation in two multiple sclerosis
patients treated with the monoclonal anti-tumor necrosis factor
antibody cA2. Neurology 1996, 47:1531-1534. [general reference]
2. The Lenercept Multiple Sclerosis Study Group and The University
of British Columbia MS/MRI Analysis Group: TNF neutralization
in MS: results of a randomized, placebo-controlled multicen-
ter study. Neurology 1999, 53:457-465. [general reference]
3. Kassiotis G, Kollias G: Uncoupling the proinflammatory from
the immunosuppressive properties of tumor necrosis factor
(TNF) at the p55 TNF receptor level: implications for patho-
genesis and therapy of autoimmune demyelination. J Exp Med
2001, 193:427-434. [general reference]
Arthritis Research    Vol 4 Suppl 3 McDevitt et al.S151
4. Jacob CO, McDevitt HO: Tumour necrosis factor-alpha in
murine autoimmune ‘lupus’ nephritis. Nature 1988, 331:356-
358. [general reference]
5. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S,
Howard M: Continuous administration of anti-interleukin 10
antibodies delays onset of autoimmunity in NZB/W F1 mice.
J Exp Med 1994, 179:305-310. [general reference]
6. Kontoyiannis D, Kollias G: Accelerated autoimmunity and lupus
nephritis in NZB mice with an engineered heterozygous defi-
ciency in tumor necrosis factor. Eur J Immunol 2000, 30:2038-
2047. [general reference]
7. Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea H: Pre-
vention of diabetes in nonobese diabetic mice by tumor
necrosis factor (TNF): similarities between TNF-alpha and
interleukin 1. Proc Natl Acad Sci USA 1990,  87:968-972.
[general reference]
8. Cope A, Ettinger R, McDevitt HO: The role of TNFα α and related
cytokines in the development and function of the autoreactive
T-cell repertoire. Res Immunol 1997, 148:307-313. [key review]
9. Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber
RD, Probert L, Kollias G, McDevitt HO: Chronic tumor necrosis
factor alters T cell responses by attenuating T cell receptor
signaling. J Exp Med 1997, 185:1573-1584. [general reference]
10. Yang XD, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD,
McDevitt HO: Effect of tumor necrosis factor alpha on insulin-
dependent diabetes mellitus in NOD mice. I. The early devel-
opment of autoimmunity and the diabetogenic process. J Exp
Med 1994, 180:995-1004. [general reference]
11. Picarella DE, Kratz A, Li CB, Ruddle NH, Flavell RA: Transgenic
tumor necrosis factor (TNF)-alpha production in pancreatic
islets leads to insulitis, not diabetes. Distinct patterns of
inflammation in TNF-alpha and TNF-beta transgenic mice.
J Immunol 1993, 150:4136-4150. [general reference]
12. McSorley SJ, Soldera S, Malherbe L, Carnaud C, Locksley RM,
Flavell RA, Glaichenhaus N: Immunological tolerance to a pan-
creatic antigen as a result of local expression of TNFalpha by
islet beta cells. Immunity 1997, 7:401-409. [general reference]
13. Quattrocchi E, Walmsley M, Browne K, Williams RO, Marinova-
Mutafchieva L, Buurman W, Butler DM, Feldmann M: Paradoxical
effects of adenovirus-mediated blockade of TNF activity in
murine collagen-induced arthritis. J Immunol 1999, 163:1000-
1009. [general reference]
14. Gordon C, Ranges GE, Greenspan JS, Wofsy D: Chronic
therapy with recombinant tumor necrosis factor-alpha in
autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol
1989, 52:421-434. [general reference]
15. Isomaki P, Panesar M, Annenkov A, Clark JM, Foxwell BM, Cher-
najovsky Y, Cope AP: Prolonged exposure of T Cells to TNF
down-regulates TCRzeta and expression of the TCR/CD3
complex at the cell surface. J Immunol 2001, 166:5495-5507.
[general reference]
16. Feldmann M, Maini RN: Anti-TNF alpha therapy of rheumatoid
arthritis: what have we learned? Annu Rev Immunol 2001, 19:
163-196. [key review]
17. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Siegel JN:
Demyelination diagnosed during etanercept (TNF receptor
fusion protein) therapy [abstract]. Arthritis Rheum 2000, 43:
S228. [general reference]
18. Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy
for inflammatory bowel disease: a review of agents, pharma-
cology, clinical results, and safety. Inflamm Bowel Dis 1999, 5:
119-133. [general reference]
19. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Got-
tlieb AB: Efficacy and safety of infliximab monotherapy for
plaque-type psoriasis: a randomised trial. Lancet 2001, 357:
1842-1847. [general reference]
20. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche
J, Almer S, Tysk C, O’Morain CA, Gassull M, Binder V, Finkel Y,
Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry
J, Colombel JF, Sahbatou M, Thomas G: Association of NOD2
leucine-rich repeat variants with susceptibility to Crohn’s
disease. Nature 2001, 411:599-603. [general reference]
21. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R,
Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR,
Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH: A
frameshift mutation in NOD2 associated with susceptibility to
Crohn’s disease. Nature 2001, 411:603-606. [general reference]
22. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C,
Willis CR, Charrier K, Morrissey PJ, Ware CB, Mohler KM: TNF
receptor-deficient mice reveal divergent roles for p55 and p75
in several models of inflammation. J Immunol 1998, 160:943-
952. [general reference]
23. Grell M, Wajant H, Zimmermann G, Scheurich P: The type 1
receptor (CD120a) is the high-affinity receptor for soluble
tumor necrosis factor. Proc Natl Acad Sci USA 1998, 95:570-
575. [general reference]
24. Eugster HP, Frei K, Bachmann R, Bluethmann H, Lassmann H,
Fontana A: Severity of symptoms and demyelination in MOG-
induced EAE depends on TNFR1. Eur J Immunol 1999, 29:626-
632. [general reference]
25. Tartaglia LA, Goeddel DV, Reynolds C, Figari IS, Weber RF,
Fendly BM, Palladino MA Jr: Stimulation of human T-cell prolif-
eration by specific activation of the 75-kDa tumor necrosis
factor receptor. J Immunol 1993, 151:4637-4641. [general refer-
ence]
26. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ:
Induction of apoptosis in mature T cells by tumour necrosis
factor. Nature 1995, 377:348-351. [general reference]
27. Wang B, Kondo S, Shivji GM, Fujisawa H, Mak TW, Sauder DN:
Tumour necrosis factor receptor II (p75) signalling is required
for the migration of Langerhans’ cells. Immunology 1996, 88:
284-288. [general reference]
28. Sheehan KC, Pinckard JK, Arthur CD, Dehner LP, Goeddel DV,
Schreiber RD: Monoclonal antibodies specific for murine p55
and p75 tumor necrosis factor receptors: identification of a
novel in vivo role for p75. J Exp Med 1995,  181:607-617.
[general reference]
29. Riminton DS, Sedgwick JD: Novel concepts of tumor necrosis
factor action in autoimmune pathology. Biologic and gene
therapy of autoimmune disease. In Current Directions in
Autoimmunity. Edited by Theofilopoulos AN. Basel: Karger; 2000.
[key review]
30. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko
AV, Boldin MP: Tumor necrosis factor receptor and Fas signal-
ing mechanisms. Annu Rev Immunol 1999, 17:331-367. [key
review]
31. Cantrell D: T cell antigen receptor signal transduction path-
ways. Annu Rev Immunol 1996, 14:259-274. [key review]
32. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM:
Increased adipose tissue expression of tumor necrosis
factor-alpha in human obesity and insulin resistance. J Clin
Invest 1995, 95:2409-2415. [general reference]
33. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM: Tumor
necrosis factor alpha inhibits signaling from the insulin
receptor. Proc Natl Acad Sci USA 1994,  91:4854-4858.
[general reference]
34. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM: Reduced
tyrosine kinase activity of the insulin receptor in obesity-dia-
betes. Central role of tumor necrosis factor-alpha. J Clin
Invest 1994, 94:1543-1549. [general reference]
35. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegel-
man BM: IRS-1-mediated inhibition of insulin receptor tyro-
sine kinase activity in TNF-alpha- and obesity-induced insulin
resistance. Science. 1996, 271:665-668. [general reference]
36. Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW,
Hotamisligil GS: Tumor necrosis factor-alpha contributes to
obesity-related hyperleptinemia by regulating leptin release
from adipocytes. J Clin Invest 1997, 100:2777-2782. [general
reference]
37. Rui L, Aguirre V, Kim LK, Shulman GI, Lee A, Corbould A, Dunaif
A, White MF: Insulin/IGF-1 and TNF-alpha stimulate phospho-
rylation of IRS-1 at inhibitory Ser307 via distinct pathways.
J Clin Invest 2001, 107:181-189. [general reference]
38. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A: Inter-
leukin-10 and the interleukin-10 receptor. Annu Rev Immunol
2001, 19:683-765. [key review]
39. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A,
Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE,
Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G,
Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke
R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO,
Staudt LM: Distinct types of diffuse large B-cell lymphoma
identified by gene expression profiling. Nature 2000, 403:503-
511. [general reference]
Available online http://arthritis-research.com/content/4/S3/S141S152
40. Wu Q, Salomon B, Chen M, Wang Y, Hoffman LM, Bluestone JA,
Fu YX: Reversal of spontaneous autoimmune insulitis in
nonobese diabetic mice by soluble lymphotoxin receptor.
J Exp Med 2001, 193:1327-1332. [general reference]
41. Ettinger R, Munson SH, Chao CC, Vadeboncoeur M, Toma J,
McDevitt HO: A critical role for lymphotoxin-beta receptor in
the development of diabetes in nonobese diabetic mice. J Exp
Med 2001, 193:1333-1340. [general reference]
42. Ware CF, VanArsdale TL, Crowe PD, Browning JL: The ligands
and receptors of the lymphotoxin system. Curr Top Microbiol
Immunol 1995, 198:175-218. [key review]
43. Rennert PD, Browning JL, Mebius R, Mackay F, Hochman PS:
Surface lymphotoxin alpha/beta complex is required for the
development of peripheral lymphoid organs. J Exp Med 1996,
184:1999-2006. [general reference]
44. Fu YX, Chaplin DD: Development and maturation of secondary
lymphoid tissues. Annu Rev Immunol 1999, 17:399-433. [key
review]
45. Kim D, Mebius RE, MacMicking JD, Jung S, Cupedo T, Castel-
lanos Y, Rho J, Wong BR, Josien R, Kim N, Rennert PD, Choi Y:
Regulation of peripheral lymph node genesis by the tumor
necrosis factor family member TRANCE. J Exp Med 2000, 192:
1467-1478. [general reference]
46. Wigle JT, Oliver G: Prox1 function is required for the develop-
ment of the murine lymphatic system. Cell 1999, 98:769-778.
[general reference]
47. Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K,
Nakao K, Nakamura K, Katsuki M, Yamamoto T, Inoue J: Severe
osteopetrosis, defective interleukin-1 signalling and lymph
node organogenesis in TRAF6-deficient mice. Genes Cells
1999, 4:353-362. [general reference]
48. Shinkura R, Kitada K, Matsuda F, Tashiro K, Ikuta K, Suzuki M,
Kogishi K, Serikawa T, Honjo T: Alymphoplasia is caused by a
point mutation in the mouse gene encoding Nf-kappa b-
inducing kinase. Nat Genet 1999,  22:74-77. [general
reference] 
49. Burkly L, Hession C, Ogata L, Reilly C, Marconi LA, Olson D,
Tizard R, Cate R, Lo D: Expression of relB is required for the
development of thymic medulla and dendritic cells. Nature
1995, 373:531-536. [general reference]
50. Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, Ryseck
RP, Lira SA, Bravo R: Multiorgan inflammation and hematopoi-
etic abnormalities in mice with a targeted disruption of RelB,
a member of the NF-kappa B/Rel family. Cell 1995, 80:331-
340. [general reference]
51. Cao X, Shores EW, Hu-Li J, Anver MR, Kelsall BL, Russell SM,
Drago J, Noguchi M, Grinberg A, Bloom ET: Defective lymphoid
development in mice lacking expression of the common
cytokine receptor gamma chain. Immunity 1995,  2:223-238.
[general reference]
52. Forster R, Mattis AE, Kremmer E, Wolf E, Brem G, Lipp M: A puta-
tive chemokine receptor, BLR1, directs B cell migration to
defined lymphoid organs and specific anatomic compartments
of the spleen. Cell 1996, 87:1037-1047. [general reference]
53. Mackay F, Majeau GR, Lawton P, Hochman PS, Browning JL:
Lymphotoxin but not tumor necrosis factor functions to main-
tain splenic architecture and humoral responsiveness in adult
mice. Eur J Immunol 1997, 27:2033-2042. [general reference]
54. Sun Z, Unutmaz D, Zou YR, Sunshine MJ, Pierani A, Brenner-
Morton S, Mebius RE, Littman DR: Requirement for RORgamma
in thymocyte survival and lymphoid organ development.
Science 2000, 288:2369-2373. [general reference]
55. Ettinger R, Browning JL, Michie SA, van Ewijk W, McDevitt HO:
Disrupted splenic architecture, but normal lymph node devel-
opment in mice expressing a soluble lymphotoxin-beta recep-
tor-IgG1 fusion protein. Proc Natl Acad Sci USA 1996,  93:
13102-13107. [general reference]
56. Wang J, Lo JC, Foster A, Yu P, Chen HM, Wang Y, Tamada K,
Chen L, Fu YX: The regulation of T cell homeostasis and
autoimmunity by T cell-derived LIGHT. J Clin Invest 2001, 108:
1771-1780. [general reference]
57. Mebius RE, Rennert P, Weissman IL: Developing lymph nodes
collect CD4+CD3– LTbeta+ cells that can differentiate to APC,
NK cells, and follicular cells but not T or B cells. Immunity
1997, 7:493-504. [general reference]
58. Wu Q, Wang Y, Wang J, Hedgeman EO, Browning JL, Fu YX:
The requirement of membrane lymphotoxin for the presence
of dendritic cells in lymphoid tissues. J Exp Med 1999, 190:
629-638. [general reference]
59. Endres R, Alimzhanov MB, Plitz T, Futterer A, Kosco-Vilbois MH,
Nedospasov SA, Rajewsky K, Pfeffer K: Mature follicular den-
dritic cell networks depend on expression of lymphotoxin
beta receptor by radioresistant stromal cells and of lympho-
toxin beta and tumor necrosis factor by B cells. J Exp Med
1999, 189:159-168. [general reference]
60. Gonzalez M, Mackay F, Browning JL, Kosco-Vilbois MH, Noelle
RJ:  The sequential role of lymphotoxin and B cells in the
development of splenic follicles. J Exp Med 1998, 187:997-
1007. [general reference]
61. Ngo VN, Korner H, Gunn MD, Schmidt KN, Riminton DS, Cooper
MD, Browning JL, Sedgwick JD, Cyster JG: Lymphotoxin
alpha/beta and tumor necrosis factor are required for stromal
cell expression of homing chemokines in B and T cell areas of
the spleen. J Exp Med 1999, 189:403-412. [general reference]
62. Luther SA, Lopez T, Bai W, Hanahan D, Cyster JG: BLC expres-
sion in pancreatic islets causes B cell recruitment and lym-
photoxin-dependent lymphoid neogenesis. Immunity 2000, 12:
471-481. [general reference]
63. Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R, Sedgwick
JD, Browning JL, Lipp M, Cyster JG: A chemokine-driven posi-
tive feedback loop organizes lymphoid follicles. Nature 2000,
406:309-314. [general reference]
64. Michie SA, Sytwu HK, McDevitt JO, Yang XD: The roles of alpha
4-integrins in the development of insulin-dependent diabetes
mellitus.  Curr Top Microbiol Immunol 1998,  231:65-83. [key
review]
65. Cyster JG: Chemokines and cell migration in secondary lym-
phoid organs. Science 1999, 286:2098-2102.
66. Suen WE, Bergman CM, Hjelmstrom P, Ruddle NH: A critical
role for lymphotoxin in experimental allergic encephalo-
myelitis. J Exp Med 1997, 186:1233-1240. [general reference]
67. Mackay F, Browning JL, Lawton P, Shah SA, Comiskey M, Bhan
AK, Mizoguchi E, Terhorst C, Simpson SJ: Both the lymphotoxin
and tumor necrosis factor pathways are involved in experi-
mental murine models of colitis. Gastroenterology 1998, 115:
1464-1475. [general reference]
68. Sakaguchi S: Regulatory T cells: controllers of immunologic
self-tolerance. Cell 2000, 101:455-458. [general reference]
69. Shevach E: Certified professionals: CD4+CD25+ suppressor T
cells. J Exp Med 2001, 193:F41-F45. [general reference]
70. Wu DY, Goldschneider I: Tolerance to cyclosporin A-induced
autologous graft-versus-host disease is mediated by a
CD4+CD25+ subset of recent thymic emigrants. J Immunol
2001, 166:7158-7164. [general reference]
71. Yang XD, Tisch R, Singer AM, Cao ZA, Liblau RS, Schreiber RD,
McDevitt HO: Effect of tumor necrosis factor alpha on insulin
dependent diabetes mellitus in NOD mice. I. The early devel-
opment of autoimmunity and the diabetogenic process. J Exp
Med 1994, 185:1573-1584. [general reference]
72. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe
A, Bluestone JA: B7/CD28 costimulation is essential for the
homeostasis of CD4+CD25+ immunoregulatory T cells that
control autoimmune diabetes. Immunity 2000,  12:431-440.
[general reference]
73. Savino W, Carnaud C, Luan JJ, Bach JF, Dardenne M: Character-
ization of the extracellular matrix-containing perivascular
spaces in the NOD mouse thymus. Diabetes  1993,  42:134-
140. [general reference]
74. O’Reilly LA, Healy D, Simpson E, Chandler P, Lund T, Ritter MA,
Cooke A: Studies on the thymus of non-obese diabetic (NOD)
mouse: effect of transgene expression. Immunology 1994,
82:275-286. [general reference]
75. Nabarra B, Andrianarson I: Thymic reticulum of autoimmune
mice. 3. Ultrastructural study of NOD (non obsese diabetic)
mouse thymus. Int J Exp Pathol 1991, 72:275-287. [general ref-
erence]
Arthritis Research    Vol 4 Suppl 3 McDevitt et al.